Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic arthritis (PsA). Methods This phase II, multicenter, randomized, double‐blind, placebo‐controlled study included t...

Ausführliche Beschreibung